Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

C. Byrd, John; Hillmen, Peter; O’Brien, Susan; C. Barrientos, Jacqueline; Reddy, Nishitha; Coutré, Steven; S. Tam, Constantine; P. Mulligan, Stephen; Jaeger, Ulrich; M. Barr, Paul; R. Furman, Richard; J. Kipps, Thomas; Thornton, Patrick; Moreno, Carol; Montillo, Marco; M. Pagel, John; A. Burger, Jan; A. Woyach, Jennifer; Dai, Sandra; Vezan, Remus; F. James, Danelle; R. Brown, Jennifer

doi:10.1182/blood-2018-08-870238

Public

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Published in Blood • Mar 6, 2019

Authors:

John C. Byrd

Peter Hillmen

Susan O’Brien

Abstract

Abstract Ibrutinib, a once-daily oral inhibitor of Bruton tyrosine kinase, has greatly improved outcomes for patients with chronic lymphocytic leukemia (CLL). The phase 3 RESONATE trial, which compared single-agent ibrutinib to ofatumumab in high-risk, relapsed patients with CLL, provided support fo...

Subject

Ibrutinib

Ofatumumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!